Business
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/trBSY4KWXHpBRzQ_5qCqbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - ","length":96,"tagName":"p"},{"type":"text","content":"- After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - ","length":138,"tagName":"p"},{"type":"text","content":"- Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit -","length":123,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT). The study, titled “Long-term Safety and Efficacy Outcomes of the Acellular Tissue Engineered Vessel (ATEV) in Extremity Arterial Trauma Repair” found that Symvess maintained structural integrity over the long term, exhibited low infection rates, and supported high rates of limb salvage in patients followed for up to 36 months.","length":751,"tagName":"p"},{"type":"text","content":""Vascular trauma is notorious for the absence of long-term follow-up data," said Rishi Kundi, MD, RPVI, FACS, FSVS, Chief of Vascular Trauma at the R Adams Cowley Shock Trauma Center of the University of Maryland. "Symvess, a bioengineered vessel, has shown remarkable limb salvage success, freedom from infection, and graft integrity and durability in a particularly high-risk population."","length":410,"tagName":"p"},{"type":"text","content":"Among the patients treated in the V005 Phase 2/3 s...